Chemistry:Umeclidinium bromide

From HandWiki
Short description: Chemical compound
Umeclidinium bromide
Clinical data
Trade namesIncruse Ellipta
Other namesGSK573719A
License data
Routes of
administration		Inhalation (DPI)
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding~89%[3]
MetabolismLiver (CYP2D6)
Elimination half-life11 hours
ExcretionFeces (58%) and urine (22%)
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
Chemical and physical data
FormulaC29H34BrNO2
Molar mass508.500 g·mol−1
3D model (JSmol)

Umeclidinium bromide, sold under the brand name Incruse Ellipta among others, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[3] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol),[5][6][7] and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol.[8]

It is on the World Health Organization's List of Essential Medicines.[9] In 2020, it was the 245th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[10][11]

References

  1. ↑ "Prescription medicines: registration of new chemical entities in Australia, 2014". 21 June 2022. https://www.tga.gov.au/resources/resource/guidance/prescription-medicines-registration-new-chemical-entities-australia-2014. 
  2. ↑ "Product monograph brand safety updates". 7 July 2016. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database/label-safety-assessment-update/product-monograph-brand-safety-updates.html. 
  3. ↑ 3.0 3.1 3.2 "Incruse Ellipta- umeclidinium aerosol, powder". 13 December 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dbb64747-1505-49d7-9a33-99dd402e96d3. 
  4. ↑ "Rolufta Ellipta (previously Rolufta)". 20 March 2017. https://www.ema.europa.eu/en/medicines/human/EPAR/rolufta-ellipta. 
  5. ↑ "Anoro Ellipta- umeclidinium bromide and vilanterol trifenatate powder". 2 June 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2dbd0671-c565-40c5-bf0f-e324db26799c. 
  6. ↑ "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease 7 (6): 311–9. December 2013. doi:10.1177/1753465813499789. PMID 24004659. 
  7. ↑ "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013. http://www.medscape.com/viewarticle/817964. 
  8. ↑ "Trelegy Ellipta- fluticasone furoate, umeclidinium bromide and vilanterol trifenatate powder". 2 June 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5a81d5a-4648-4c7a-951d-33c014a63c7e. 
  9. ↑ World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. WHO/MHP/HPS/EML/2021.02. 
  10. ↑ "The Top 300 of 2020". https://clincalc.com/DrugStats/Top300Drugs.aspx. 
  11. ↑ "Umeclidinium - Drug Usage Statistics". https://clincalc.com/DrugStats/Drugs/Umeclidinium. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Umeclidinium_bromide&oldid=4028498"